Using Pentoxifylline to Help Treat Ulcerative Colitis
Clinical Study to Evaluate the Possible Efficacy of Pentoxifylline in Patients With Ulcerative Colitis Treated With Mesalamine
This study is testing if the medication Pentoxifylline can help adults with ulcerative colitis feel better by reducing inflammation and improving their symptoms.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Mansoura) |
| Trial ID | NCT05558761 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of Pentoxifylline as an adjunctive therapy for patients suffering from ulcerative colitis, a chronic inflammatory bowel disease. The study aims to understand how this medication can potentially reduce inflammation and improve symptoms associated with the condition. Participants will receive Pentoxifylline at a dosage of 400 MG, and the trial will assess its effectiveness in managing the disease. The trial is designed for adults aged 18 and older, focusing on those who meet specific inclusion criteria while excluding individuals with certain health conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with ulcerative colitis who do not have severe disease or other specified health issues.
Not a fit: Patients with severe ulcerative colitis, colorectal cancer, or significant liver and kidney function abnormalities may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide significant relief and improved quality of life for patients with ulcerative colitis.
How similar studies have performed: While the specific use of Pentoxifylline in ulcerative colitis is less common, similar studies exploring adjunctive therapies for inflammatory bowel diseases have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Age ≥ 18 years Both males and females will be included Negative pregnancy test and effective contraception Exclusion Criteria: - Breastfeeding Significant liver and kidney function abnormalities Colorectal cancer patients Patients with severe UC Patients taking rectal or systemic steroids Known allergy to the studied medications
Where this trial is running
Mansoura
- Faculty of Medicine, Mansoura University — Mansoura, Egypt (Recruiting)
Study contacts
- Principal investigator: Mostafa M Bahaa, PhD — Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt
- Study coordinator: Mostafa M Bahaa, PhD
- Email: mbahaa@horus.edu.eg
- Phone: 0201025538337
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.